Nano-antioxidants for neurodegenerative disorders: a scoping review
Source abstract
Abstract
BACKGROUND: Antioxidants showed usefulness in treating or preventing neurodegenerative diseases (NDDs). However, antioxidants have limited bioavailability owing to the BBB limiting drug access to the CNS. Nano drug delivery systems (NDDS) provide innovative solutions to pass the BBB and enhance antioxidant activity. Although an incredible number of preclinical trials are in the literature, it has not been translated into clinical practice. OBJECTIVES: This scoping review aims to systematically summarize the current evidence, study the characteristics of the available literature, and identify research gaps. METHODS: This review was conducted following the PRISMA-ScR guidelines. We searched PubMed for all primary studies investigating nano-antioxidants in the context of NDDs within the last five years. Data were extracted and analyzed on the year of publication, contributing affiliations, type of research, the investigational antioxidant agent, and the drug delivery matrix. In addition, we examined the association between NDDS and the year of publication, plus the association with the country of publication. RESULTS: A total of 171 were included in the analysis. We found that all the articles included were pre-clinical trials. Organic and lipid-nanocarriers were the most frequently adopted (31.95% and 26.04%, respectively). Surprisingly, nanoplatforms were mentioned in only one trial. Our analysis showed that only 24 articles (14.04%) of the included trials adopted comparative studies. CONCLUSION AND FUTURE IMPLICATIONS: We noticed a significant underrepresentation of nanoplatform applications and comparative designs. We provided new insights into nanoplatforms research. Moreover, we believe that it is crucial to establish rigorous validation systems and methodological approaches to predict the destiny of these nanocarriers in vivo and inspire the formulation of cost-effective functionalized nanoparticles with less stability or sterility drawbacks.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Mendez MF, McMurtray AM. Neurodegenerative disorders. In: Encyclopedia of stress. Elsevier; 2007. pp. 840–4.10.1016/B978-012373947-6/00575-4 ↗
2. Suescun J, Chandra S, Schiess MC. The role of neuroinflammation in neurodegenerative disorders. In: translational inflammation. Elsevier; 2019. pp. 241–67.10.1016/B978-0-12-813832-8.00013-3 ↗
3. Sahoo RK, Gupta T, Smily, Kumar V, Rani S, Gupta U. Aetiology and pathophysiology of neurodegenerative disorders. In: Nanomedical drug delivery for neurodegenerative diseases. Elsevier; 2022. pp. 1–16.10.1016/B978-0-323-85544-0.00006-X ↗
4. Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499–502.10.1242/dmm.030205 ↗
5. Schependom JV, D’haeseleer M. Advances in Neurodegenerative Diseases. J Clin Med. 2023 Feb;12(5):1709.10.3390/jcm12051709 ↗
6. Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23(3):1851.10.3390/ijms23031851 ↗
7. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect. 2005;113(9):1250–6.10.1289/ehp.7567 ↗
8. Olufunmilayo EO, Gerke-Duncan MB, Holsinger RMD. Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants. 2023;12(2):517.10.3390/antiox12020517 ↗
9. Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, Costăchescu B, Grumezescu AM, Teleanu RI. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci. 2022;23(11):5938.10.3390/ijms23115938 ↗
10. Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res. 2017;39(1):73–82.10.1080/01616412.2016.1251711 ↗
11. Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Chakole RD, Nemade LS, Kale NK, Borah S, Deokar SS, Behera A, Bhandari DD, Gaikwad N, Azad AK, Ghosh A. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis—an updated review. Mitochondrion. 2023;71:83–92.10.1016/j.mito.2023.05.007 ↗
12. He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 2017;44(2):532–53.10.1159/000485089 ↗
13. Guerra-Araiza C, Álvarez-Mejía AL, Sánchez-Torres S, Farfan-García E, Mondragón-Lozano R, Pinto-Almazán R, Salgado-Ceballos H. Effect of natural exogenous antioxidants on aging and on neurodegenerative diseases. Free Radical Res. 2013;47(6–7):451–62.10.3109/10715762.2013.795649 ↗
14. Neha K, Haider MR, Pathak A, Yar MS. Medicinal prospects of antioxidants: a review. Eur J Med Chem. 2019;178:687–704.10.1016/j.ejmech.2019.06.010 ↗
15. Casetta I, Govoni V, Granieri E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Des. 2005;11(16):2033–52.10.2174/1381612054065729 ↗
16. Teleanu DM, Chircov C, Grumezescu AM, Teleanu RI. Neuronanomedicine: an up-to-date overview. Pharmaceutics. 2019;11(3):101.10.3390/pharmaceutics11030101 ↗
17. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21–78.10.1152/physrev.00050.2017 ↗
18. Feng J, Zheng Y, Guo M, Ares I, Martínez M, Lopez-Torres B, Martínez-Larrañaga MR, Wang X, Anadón A, Martínez MA. Oxidative stress, the blood–brain barrier and neurodegenerative diseases: the critical beneficial role of dietary antioxidants. Acta Pharmaceutica Sinica B. 2023;13(10):3988–4024.10.1016/j.apsb.2023.07.010 ↗
19. Watal G, Watal A, Rai PK, Rai DK, Sharma G, Sharma B. Biomedical applications of nano-antioxidant. In 2013. pp. 147–51.10.1007/978-1-62703-475-3_9 ↗
20. Sandhir R, Yadav A, Sunkaria A, Singhal N. Nano-antioxidants: an emerging strategy for intervention against neurodegenerative conditions. Neurochem Int. 2015;89:209–26.10.1016/j.neuint.2015.08.011 ↗
21. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28(1):1–13.10.1081/DDC-120001481 ↗
22. Li CW, Li LL, Chen S, Zhang JX, Lu WL. Antioxidant nanotherapies for the treatment of inflammatory diseases. Front Bioeng Biotechnol. 2020;8.10.3389/fbioe.2020.00200 ↗
23. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S, Chalfant C, Conrad DH, Kepley CL. Epoxyeicosatrienoic acids are involved in the C70 fullerene derivative–induced control of allergic asthma. J Allergy Clin Immunol. 2012;130(3):761-769.e2.10.1016/j.jaci.2012.04.023 ↗
24. Kotcherlakota R, Barui AK, Prashar S, Fajardo M, Briones D, Rodríguez-Diéguez A, Patra CR, Gómez-Ruiz S. Curcumin loaded mesoporous silica: an effective drug delivery system for cancer treatment. Biomater Sci. 2016;4(3):448–59.10.1039/C5BM00552C ↗
25. Kalashnikova I, Mazar J, Neal CJ, Rosado AL, Das S, Westmoreland TJ, Seal S. Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma. Nanoscale. 2017;9(29):10375–87.10.1039/C7NR02770B ↗
26. Joseph A, Wood T, Chen CC, Corry K, Snyder JM, Juul SE, Parikh P, Nance E. Curcumin-loaded polymeric nanoparticles for neuroprotection in neonatal rats with hypoxic-ischemic encephalopathy. Nano Res. 2018;11(10):5670–88.10.1007/s12274-018-2104-y ↗
27. Kang DW, Kim CK, Jeong HG, Soh M, Kim T, Choi IY, Ki SK, Kim DY, Yang W, Hyeon T, Lee SH. Biocompatible custom ceria nanoparticles against reactive oxygen species resolve acute inflammatory reaction after intracerebral hemorrhage. Nano Res. 2017;10(8):2743–60.10.1007/s12274-017-1478-6 ↗
28. Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HAM, Abdelgawad MA, Mostafa EM. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. Polymers. 2023;15(5):1123.10.3390/polym15051123 ↗
29. Ferrão R, Rai A. Advanced polymeric nanoparticles for the treatment of neurodegenerative diseases. Chem Phys Polym Nanocompos Proc Morphol Struct Thermodyn Rheol. 2024;3:843–85. https://doi.org/10.1002/9783527837021.ch27.10.1002/9783527837021.ch27 ↗
30. Jin L, Zeng X, Liu M, Deng Y, He N. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014;4(3):240–55.10.7150/thno.6914 ↗
31. Jin L, Nie L, Deng Y, Khana GJ, He N. The application of polymeric nanoparticles as drug delivery carriers to cells in neurodegenerative diseases. Cell Prolif. 2025. https://doi.org/10.1111/cpr.13804.10.1111/cpr.13804 ↗
32. Colby AH, Liu R, Doyle RP, Merting A, Zhang H, Savage N, Chu NQ, Hollister BA, McCulloch W, Burdette JE, Pearce CJ, Liu K, Oberlies NH, Colson YL, Grinstaff MW. Pilot-scale production of expansile nanoparticles: practical methods for clinical scale-up. J Control Release. 2021;337:144–54.10.1016/j.jconrel.2021.07.012 ↗
33. Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discover Nano. 2023;18(1):157.10.1186/s11671-023-03943-0 ↗
34. Binda A, Murano C, Rivolta I. Innovative therapies and nanomedicine applications for the treatment of Alzheimer’s disease: a state-of-the-art (2017–2020). Int J Nanomed. 2020;15:6113–35.10.2147/IJN.S231480 ↗
35. Paul W, Sharma CP. Inorganic nanoparticles for targeted drug delivery. In: Biointegration of medical implant materials [Internet]. Elsevier; 2020. pp. 333–73. Available from: https://linkinghub.elsevier.com/retrieve/pii/B978008102680900013510.1016/B978-0-08-102680-9.00013-5 ↗
36. Lyu N, Sun B, Tukova A, Zhang Q, Gu Z, Wang Y. In situ synthesis of gold nanoparticles on layered double hydroxide nanoparticles for multiplexing molecular imaging of single cells. Mater Today Chem. 2023;33: 101698.10.1016/j.mtchem.2023.101698 ↗
37. Zorkina Y, Abramova O, Ushakova V, Morozova A, Zubkov E, Valikhov M, Melnikov P, Majouga A, Chekhonin V. Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: advantages and limitations. Molecules. 2020;25(22):5294.10.3390/molecules25225294 ↗
38. Gao N, Sun H, Dong K, Ren J, Qu X. Gold‐nanoparticle‐based multifunctional amyloid‐β inhibitor against Alzheimer’s disease. Chem Eur J. 2015;21(2):829–35.10.1002/chem.201404562 ↗
39. Wu T, Tang M. The inflammatory response to silver and titanium dioxide nanoparticles in the central nervous system. Nanomedicine. 2018;13(2):233–49.10.2217/nnm-2017-0270 ↗
40. Slepičková Kasálková N, Slepička P, Švorčík V. Carbon nanostructures, nanolayers, and their composites. Nanomaterials. 2021;11(9):2368.10.3390/nano11092368 ↗
41. Li Z, Wang L, Li Y, Feng Y, Feng W. Carbon-based functional nanomaterials: preparation, properties and applications. Compos Sci Technol. 2019;179:10–40.10.1016/j.compscitech.2019.04.028 ↗
42. Liu W, Speranza G. Functionalization of carbon nanomaterials for biomedical applications. C. 2019;5(4):72.10.3390/c5040072 ↗
43. Elsayed M. Carbon nanostructures as promising targeted drug delivery systems of anticancer agents. Int J Cancer Biomed Res. 2024;8(1):1–15.10.21608/jcbr.2024.250410.1323 ↗
44. Costa PM, Bourgognon M, Wang JTW, Al-Jamal KT. Functionalised carbon nanotubes: from intracellular uptake and cell-related toxicity to systemic brain delivery. J Control Release. 2016;241:200–19.10.1016/j.jconrel.2016.09.033 ↗
45. Kaushik N, Borkar SB, Nandanwar SK, Panda PK, Choi EH, Kaushik NK. Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnol. 2022;20(1):152.10.1186/s12951-022-01364-2 ↗
46. Ashfaq M, Talreja N, Chuahan D, Srituravanich W. Carbon nanostructure-based materials: A novel tool for detection of Alzheimer’s disease. In: Biological, diagnostic and therapeutic advances in Alzheimer’s disease [Internet]. Singapore: Springer Singapore; 2019. pp. 71–89. Available from: http://link.springer.com/https://doi.org/10.1007/978-981-13-9636-6_410.1007/978-981-13-9636-6_4 ↗
47. Gustavsson P, Hedmer M, Rissler J. Carbon nanotubes—exposure, toxicology and protective measures in the work environment. 2011;1.
48. Tzur-Balter A, Shatsberg Z, Beckerman M, Segal E, Artzi N. Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues. Nat Commun. 2015;6(1):6208.10.1038/ncomms7208 ↗
49. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed. 2007;46(40):7548–58.10.1002/anie.200604488 ↗
50. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP. Mesoporous silicon in drug delivery applications. J Pharm Sci. 2008;97(2):632–53.10.1002/jps.20999 ↗
51. Shahbazi MA, Herranz B, Santos HA. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter. 2012;2(4):296–312.10.4161/biom.22347 ↗
52. Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim HW, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. Journal of Tissue Engineering [Internet]. 2013 Jan;4. Available from: https://journals.sagepub.com/doi/https://doi.org/10.1177/204173141350335710.1177/2041731413503357 ↗
53. Rosenholm JM, Sahlgren C, Lindén M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles—opportunities & challenges. Nanoscale. 2010;2(10):1870.10.1039/c0nr00156b ↗
54. Huang X, Zhuang J, Teng X, Li L, Chen D, Yan X, Tang F. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials. 2010;31(24):6142–53.10.1016/j.biomaterials.2010.04.055 ↗
55. Heggannavar GB, Hiremath CG, Achari DD, Pangarkar VG, Kariduraganavar MY. Development of doxorubicin-loaded magnetic silica-pluronic F-127 nanocarriers conjugated with transferrin for treating glioblastoma across the blood-brain barrier using an in vitro model. ACS Omega. 2018;3(7):8017–26.10.1021/acsomega.8b00152 ↗
56. Attia MS, Yahya A, Monaem NA, Sabry SA. Mesoporous silica nanoparticles: their potential as drug delivery carriers and nanoscavengers in Alzheimer’s and Parkinson’s diseases. Saudi Pharm J. 2023;31(3):417–32.10.1016/j.jsps.2023.01.009 ↗
57. Cai H, Liu D, Xue WW, Ma L, Xie HT, Ning K. Lipid-based nanoparticles for drug delivery in Parkinson’s disease. Translational Neuroscience [Internet]. 2024 Dec;15(1). Available from: https://www.degruyter.com/document/doi/https://doi.org/10.1515/tnsci-2022-0359/html10.1515/tnsci-2022-0359/html ↗
58. Cano A, Espina M, García ML. Recent advances on antitumor agents-loaded polymeric and lipid-based nanocarriers for the treatment of brain cancer. Curr Pharm Des. 2020;26(12):1316–30.10.2174/1381612826666200116142922 ↗
59. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s Disease and Parkinson’s Disease). J Drug Deliv. 2011;2011:1–12.10.1155/2011/469679 ↗
60. Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Patel RJ, Ajazuddin, Ravichandiran V, Murty US, Alexander A. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2020;321:372–415.10.1016/j.jconrel.2020.02.020 ↗
61. Angelova A, Garamus VM, Angelov B, Tian Z, Li Y, Zou A. Advances in structural design of lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor agents. Adv Coll Interface Sci. 2017;249:331–45.10.1016/j.cis.2017.04.006 ↗
62. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11(1):159.10.1186/1476-511X-11-159 ↗
63. Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, Malungelo Khamanga SM, Makoni PA. Lipid-based nanocarriers for neurological disorders: a review of the state-of-the-art and therapeutic success to date. Pharmaceutics. 2022;14(4):836.10.3390/pharmaceutics14040836 ↗
64. Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au. 2023;3(6):600–19.10.1021/acsmaterialsau.3c00032 ↗
65. Ball R, Bajaj P, Whitehead K. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int J Nanomed. 2016;12:305–15.10.2147/IJN.S123062 ↗
66. Scoping [Internet]. PRISMA statement. [cited 2025 May 19]. Available from: https://www.prisma-statement.org/scoping
67. Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, DE Lillo A, Laino L, Lo Muzio L. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med. 2015 Nov;10(5):1615–23.10.3892/etm.2015.2749 ↗
68. Stanić Z. Curcumin, a compound from natural sources, a true scientific challenge—a review. Plant Foods Hum Nutr. 2017;72(1):1–12.10.1007/s11130-016-0590-1 ↗
69. Katila N, Duwa R, Bhurtel S, Khanal S, Maharjan S, Jeong JH, Lee S, Choi DY, Yook S. Enhancement of blood-brain barrier penetration and the neuroprotective effect of resveratrol. J Control Release. 2022;346:1–19.10.1016/j.jconrel.2022.04.003 ↗
70. Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci [Internet]. 2014 Sep 11 [cited 2024 Aug 6];6. Available from: https://www.frontiersin.org/journals/aging-neuroscience/articles/https://doi.org/10.3389/fnagi.2014.00218/full10.3389/fnagi.2014.00218/full ↗
71. Abozaid OAR, Sallam MW, El-Sonbaty S, Aziza S, Emad B, Ahmed ESA. Resveratrol-selenium nanoparticles alleviate neuroinflammation and neurotoxicity in a rat model of Alzheimer’s disease by regulating Sirt1/miRNA-134/GSK3β expression. Biol Trace Elem Res. 2022;200(12):5104–14.10.1007/s12011-021-03073-7 ↗
72. Zhang L, Yang S, Wong LR, Xie H, Ho PCL. In vitro and in vivo comparison of curcumin-encapsulated chitosan-coated poly(lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s disease. Mol Pharm. 2020;17(11):4256–69.10.1021/acs.molpharmaceut.0c00675 ↗
73. Sadegh Malvajerd S, Izadi Z, Azadi A, Kurd M, Derakhshankhah H, Sharifzadeh M, Akbari Javar H, Hamidi M. Neuroprotective potential of curcumin-loaded nanostructured lipid carrier in an animal model of Alzheimer’s disease: behavioral and biochemical evidence. J Alzheimers Dis. 2019;69(3):671–86.10.3233/JAD-190083 ↗
74. Gao C, Wang Y, Sun J, Han Y, Gong W, Li Y, Feng Y, Wang H, Yang M, Li Z, Yang Y, Gao C. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer’s disease mice. Acta Biomater. 2020;108:285–99.10.1016/j.actbio.2020.03.029 ↗
75. Mehanny M, Hathout RM, Geneidi AS, Mansour S. Exploring the use of nanocarrier systems to deliver the magical molecule; curcumin and its derivatives. J Control Release. 2016;10(225):1–30.10.1016/j.jconrel.2016.01.018 ↗
76. Agrawal M, Saraf S, Pradhan M, Patel RJ, Singhvi G, Ajazuddin null, Alexander A. Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. Biomed Pharmacother. 2021;141:111919.10.1016/j.biopha.2021.111919 ↗
77. Mursaleen L, Somavarapu S, Zariwala MG. Deferoxamine and curcumin loaded nanocarriers protect against rotenone-induced neurotoxicity. J Parkinsons Dis. 2020;10(1):99–111.10.3233/JPD-191754 ↗
78. Huang R, Zhu Y, Lin L, Song S, Cheng L, Zhu R. Solid lipid nanoparticles enhanced the neuroprotective role of curcumin against epilepsy through activation of Bcl-2 family and P38 MAPK pathways. ACS Chem Neurosci. 2020;11(13):1985–95.10.1021/acschemneuro.0c00242 ↗
79. Ganugula R, Arora M, Jaisamut P, Wiwattanapatapee R, Jørgensen HG, Venkatpurwar VP, Zhou B, Rodrigues Hoffmann A, Basu R, Guo S, Majeti NVRK. Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of type 1 diabetes mellitus. Br J Pharmacol. 2017;174(13):2074–84.10.1111/bph.13816 ↗
80. Galindo R, Sánchez-López E, Gómara MJ, Espina M, Ettcheto M, Cano A, Haro I, Camins A, García ML. Development of peptide targeted PLGA-PEGylated nanoparticles loading licochalcone-A for ocular inflammation. Pharmaceutics. 2022;14(2):285.10.3390/pharmaceutics14020285 ↗
81. Abdel-Hafez SM, Hathout RM, Sammour OA. Towards better modeling of chitosan nanoparticles production: screening different factors and comparing two experimental designs. Int J Biol Macromol. 2014;64:334–40.10.1016/j.ijbiomac.2013.11.041 ↗
82. Yang L, Wang Y, Li Z, Wu X, Mei J, Zheng G. Brain targeted peptide-functionalized chitosan nanoparticles for resveratrol delivery: impact on insulin resistance and gut microbiota in obesity-related Alzheimer’s disease. Carbohydr Polym. 2023;15(310): 120714.10.1016/j.carbpol.2023.120714 ↗
83. Zhang B, Zhao Y, Guo K, Tian H, Wang C, Wang R, Chen Y, Chen X, Zheng H, Gao B, Shen J, Tian W. Macromolecular nanoparticles to attenuate both reactive oxygen species and inflammatory damage for treating Alzheimer’s disease. Bioeng Transl Med. 2022;8(3): e10459.10.1002/btm2.10459 ↗
84. Ozdal ZD, Sahmetlioglu E, Narin I, Cumaoglu A. Synthesis of gold and silver nanoparticles using flavonoid quercetin and their effects on lipopolysaccharide induced inflammatory response in microglial cells. 3 Biotech. 2019;9(6):212.10.1007/s13205-019-1739-z ↗
85. Halevas E, Mavroidi B, Nday CM, Tang J, Smith GC, Boukos N, Litsardakis G, Pelecanou M, Salifoglou A. Modified magnetic core-shell mesoporous silica nano-formulations with encapsulated quercetin exhibit anti-amyloid and antioxidant activity. J Inorg Biochem. 2020;213: 111271.10.1016/j.jinorgbio.2020.111271 ↗
86. Rananaware P, Pandit P, Naik S, Mishra M, Keri RS, Brahmkhatri VP. Anti-amyloidogenic property of gold nanoparticle decorated quercetin polymer nanorods in pH and temperature induced aggregation of lysozyme. RSC Adv. 2022;12(36):23661–74.10.1039/D2RA03121C ↗
87. Alaqeel NK, AlSheikh MH, Al-Hariri MT. Quercetin nanoemulsion ameliorates neuronal dysfunction in experimental Alzheimer’s disease model. Antioxidants (Basel). 2022;11(10):1986.10.3390/antiox11101986 ↗
88. Amanzadeh Jajin E, Esmaeili A, Rahgozar S, Noorbakhshnia M. Quercetin-conjugated superparamagnetic iron oxide nanoparticles protect AlCl3-induced neurotoxicity in a rat model of Alzheimer’s disease via antioxidant genes, APP gene, and miRNA-101. Front Neurosci. 2020;14: 598617.10.3389/fnins.2020.598617 ↗
89. Eze FN, Eze RC, Ovatlarnporn C. Insights into the remarkable attenuation of hen egg white lysozyme amyloid fibril formation mediated by biogenic gold nanoparticles stabilized by quercetin-functionalized tara gum. Int J Biol Macromol. 2023;31(232): 123044.10.1016/j.ijbiomac.2022.12.263 ↗
90. Shehata MK, Ismail AA, Kamel MA. Combined donepezil with astaxanthin via nanostructured lipid carriers effective delivery to brain for Alzheimer’s disease in rat model. Int J Nanomed. 2023;18:4193–227.10.2147/IJN.S417928 ↗
91. Liu Y, Hong H, Xue J, Luo J, Liu Q, Chen X, Pan Y, Zhou J, Liu Z, Chen T. Near-infrared radiation-assisted drug delivery nanoplatform to realize blood-brain barrier crossing and protection for parkinsonian therapy. ACS Appl Mater Interfaces. 2021;13(31):37746–60.10.1021/acsami.1c12675 ↗
92. Wu Q, Chen L, Huang X, Lin J, Gao J, Yang G, Wu Y, Wang C, Kang X, Yao Y, Wang Y, Xue M, Luan X, Chen X, Zhang Z, Sun S. A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models. Int J Oral Sci. 2023;15(1):1–12.10.1038/s41368-022-00211-2 ↗
93. Chen W, Ouyang J, Yi X, Xu Y, Niu C, Zhang W, Wang L, Sheng J, Deng L, Liu YN, Guo S. Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv Mater. 2018;30(3).10.1002/adma.201703458 ↗
94. Gong L, Zhang X, Ge K, Yin Y, Machuki JO, Yang Y, Shi H, Geng D, Gao F. Carbon nitride-based nanocaptor: an intelligent nanosystem with metal ions chelating effect for enhanced magnetic targeting phototherapy of Alzheimer’s disease. Biomaterials. 2021;267: 120483.10.1016/j.biomaterials.2020.120483 ↗
95. Zhang H, Dong S, Li Z, Feng X, Xu W, Tulinao CMS, Jiang Y, Ding J. Biointerface engineering nanoplatforms for cancer-targeted drug delivery. Asian J Pharm Sci. 2020;15(4):397–415.
96. Mohamad T, Badri W, Greige-Gerges H, Fessi H, Elaïssari A. Nanoparticles/nanoplatform to carry and deliver the drug molecules to the target site. In: Drug delivery devices and therapeutic systems [Internet]. 2021 [cited 2024 Aug 6]. pp. 249–66. Available from: https://hal.science/hal-0300139310.1016/B978-0-12-819838-4.00009-2 ↗
97. Reyna-Lázaro L, Morales-Becerril A, Aranda-Lara L, Isaac-Olivé K, Ocampo-García B, Gibbens-Bandala B, Olea-Mejía O, Morales-Avila E. Pharmaceutical nanoplatforms based on self-nanoemulsifying drug delivery systems for optimal transport and co-delivery of siRNAs and anticancer drugs. J Pharm Sci. 2024;113(7):1907–18.10.1016/j.xphs.2024.02.017 ↗
98. T Cell‐Mediated Transport of Polymer Nanoparticles across the Blood–Brain Barrier - Ayer - 2021 - Advanced Healthcare Materials - Wiley Online Library [Internet]. [cited 2024 Aug 6]. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/adhm.20200137510.1002/adhm.202001375 ↗
99. Yu H, Yang Z, Li F, Xu L, Sun Y. Cell-mediated targeting drugs delivery systems. Drug Deliv. 2020;27(1):1425–37.10.1080/10717544.2020.1831103 ↗
100. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–87.10.1007/s11095-016-1958-5 ↗